A consumer group called it “an outrage” because of the amount taxpayers invested toward the drug's development.
The Food and Drug Administration on Monday announced it was revoking emergency authorization of two malaria drugs touted by President Trump as a possible “‘game changer”’ in the fight against COVID-19.
Dr. Rick Bright alleges he was reassigned to a lesser role because he resisted political pressure to allow widespread use of hydroxychloroquine, a malaria drug favored by President Trump.
Word of the drug came as the U.S. government reported that American economic output is shriveling in the biggest and fastest collapse since the Great Depression.
Two studies released this week found that hydroxychloroquine and chloroquine led to more fatalities among coronavirus patients.
For dispensaries, 4/20 is usually their Black Friday, when sales soar. Instead, they are reporting up-and-down buying and pondering an uncertain future.
Ignoring medical experts and scientists, Trump has aggressively promoted hydroxychloroquine, while acknowledging that he isn’t a doctor and instead relies on “common sense.”